Pulse Biosciences, Inc.
PLSE
$13.18
-$0.07-0.53%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 79.99% | 86.38% | 74.51% | 51.62% | 32.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 62.86% | 56.60% | 42.71% | 29.11% | 22.00% |
| Operating Income | -62.68% | -56.60% | -42.71% | -29.11% | -21.98% |
| Income Before Tax | -61.99% | -54.54% | -41.59% | -26.95% | -16.87% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -61.99% | -54.54% | -41.59% | -26.95% | -16.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -61.99% | -54.54% | -41.59% | -26.95% | -16.87% |
| EBIT | -62.68% | -56.60% | -42.71% | -29.11% | -21.98% |
| EBITDA | -64.47% | -58.26% | -43.99% | -30.00% | -22.80% |
| EPS Basic | -41.74% | -35.43% | -21.92% | -1.93% | 11.98% |
| Normalized Basic EPS | -41.73% | -35.45% | -21.92% | -1.91% | 11.49% |
| EPS Diluted | -41.74% | -35.43% | -21.92% | -1.93% | 11.98% |
| Normalized Diluted EPS | -41.73% | -35.45% | -21.92% | -1.91% | 11.49% |
| Average Basic Shares Outstanding | 14.50% | 13.83% | 15.01% | 21.51% | 29.77% |
| Average Diluted Shares Outstanding | 14.50% | 13.83% | 15.01% | 21.51% | 29.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |